Mirimus is an award-winning New York biotech company that propels the scientific research behind medical breakthroughs. Established in 2010 out of Cold Spring Harbor Laboratory with the mission to transform its cutting-edge RNA interference technologies into effective gene silencing therapeutics, Mirimus is a best-in-class innovator addressing health issues on a global scale by pioneering new ways to diagnose and treat diseases. When struck by COVID-19, Mirimus used its scientific and operational expertise to radically change testing by creating a fast, cheap and scalable solution. Now, Mirimus’ business operations include three areas: Drug Discovery, RNAi Therapeutics and Molecular Diagnostics. Currently, Mirimus is redeploying COVID-19 revenues into R&D for preclinical validation of novel therapeutics and to develop lower cost screening and diagnostic approaches to monitor chronic disease and improve healthcare outcomes.